| dc.contributor | 科管智財所 | |
| dc.creator (作者) | 陳秉訓 | |
| dc.creator (作者) | Chen, Ping-Hsun | |
| dc.date (日期) | 2020-12 | |
| dc.date.accessioned | 17-六月-2021 15:43:58 (UTC+8) | - |
| dc.date.available | 17-六月-2021 15:43:58 (UTC+8) | - |
| dc.date.issued (上傳時間) | 17-六月-2021 15:43:58 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/135854 | - |
| dc.description.abstract (摘要) | IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc., 966 F.3d 1374 (Fed. Cir. 2020), shows a case of inaccurate translation leading the court to find the asserted claims invalid. The disputed term “half-liquid” was found unclear in terms of whether pastes and gels should fall within or be excluded from the patentee`s construction of “half-liquid.” This article examines the IBSA case and argues that there could have been a chance to avoid such mistake. This article also demonstrates that the translation error is not correctable under 35 U.S.C. § 255. | |
| dc.format.extent | 140757 bytes | - |
| dc.format.mimetype | application/pdf | - |
| dc.relation (關聯) | Biotechnology Law Report, Vol.39, No.6, pp.452-457 | |
| dc.subject (關鍵詞) | Tirosint ; indefiniteness ; new abbreviated drug application ; semi-liquid ; half-liquid | |
| dc.title (題名) | Incorrect Translation Causing a Claim to Be Indefinite Under 35 U.S.C. § 112—A Case Study of IBSA Institut Biochimique, S.A. v. Teva Pharmaceuticals USA, Inc. | |
| dc.type (資料類型) | article | |
| dc.identifier.doi (DOI) | 10.1089/blr.2020.29208.phc | |
| dc.doi.uri (DOI) | https://doi.org/10.1089/blr.2020.29208.phc | |
